The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Alcohol, Cannabis, and Opioid Use Disorders, and Disease Burden in an Integrated Health Care System
Open accessAbstract
OBJECTIVES: We examined prevalence of major medical conditions and extent of disease burden among patients with and without substance use disorders (SUDs) in an integrated health care system serving 3.8 million members. METHODS: Medical conditions and SUDs were extracted from electronic health records in 2010. Patients with SUDs (n = 45,461; alcohol, amphetamine, barbiturate, cocaine, hallucinogen, and opioid) and demographically matched patients without SUDs (n = 45,461) were compared on the prevalence of 19 major medical conditions. Disease burden was measured as a function of 10-year mortality risk using the Charlson Comorbidity Index. P-values were adjusted using Hochberg's correction for multiple-inference testing within each medical condition category. RESULTS: The most frequently diagnosed SUDs in 2010 were alcohol (57.6%), cannabis (14.9%), and opioid (12.9%). Patients with these SUDs had higher prevalence of major medical conditions than non-SUD patients (alcohol use disorders, 85.3% vs 55.3%; cannabis use disorders, 41.9% vs 23.0%; and opioid use disorders, 44.9% vs 26.1%; all P < 0.001). Patients with these SUDs also had higher disease burden than non-SUD patients; patients with opioid use disorders (M = 0.48; SE = 1.46) had particularly high disease burden (M = 0.23; SE = 0.09; P < 0.001). CONCLUSIONS: Common SUDs, particularly opioid use disorders, are associated with substantial disease burden for privately insured individuals without significant impediments to care. This signals the need to explore the full impact SUDs have on the course and outcome of prevalent conditions and initiate enhanced service engagement strategies to improve disease burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“individuals receiving integrated care experience enhanced treatment engagement, reduced substance use, improved mental health, and an overall better quality of life [20,21].”
From Navigating the Complex Intersection of Substance Use and Psychiatric Disorders: A Comprehensive Review (2024) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Whiteford, H. A., Degenhardt, L., Rehm, J., Baxter, A. J., Ferrari, A. J., Erskine, H. E., Charlson, F. J., Norman, R. E., Flaxman, A. D., Johns, N., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61611-6 · Cited by 6,006
A sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Extent of illicit drug use and dependence, and their contribution to the global burden of disease
Degenhardt, L. J., & Hall, W. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61138-0 · Cited by 1,354
Adverse health effects of non-medical cannabis use
Hall, W., & Degenhardt, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61037-0 · Cited by 1,134
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,014
Charlson, M. E., Charlson, R. E., Peterson, J. C., Marinopoulos, S. S., Briggs, W. M., & Hollenberg, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.01.006 · Cited by 894 · cited 4×
“This measure yields a weighted score predicting 10-year mortality risk for patients who present for treatment with a range of diagnosis-based comorbid medical conditions (Charlson et al., 2008).”
BackgroundMethodInfluentialDegenhardt, L. J., Whiteford, H., Ferrari, A. J., Baxter, A. J., Charlson, F., Hall, W., Freedman, G., Burstein, R., Johns, N. E., Engell, R. E., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61530-5 · Cited by 873
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Societal costs of prescription opioid abuse, dependence, and misuse in the United States
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01075.x · Cited by 644
Cited by
Sorted by citations
Items 101–126 of 126
Smith, M. D., Kromash, R., Siebert, S. L., Gratz, K. L., Moore, K. E., & Tull, M. T. (2024) · Substance Use & Misuse · doi:10.1080/10826084.2024.2403122 · Cited by 1
González, E. M. Q., Gadea, M., & Espert, R. (2024) · Revista Española de Drogodependencias · doi:10.54108/10085 · Cited by 1
Chowdhury, D. (2021) · The Journal of Mental Health Training Education and Practice · doi:10.1108/jmhtep-06-2021-0070 · Cited by 1
State-of-The-Art Treatment of Opioid Use Disorder
Mooney, L. J., & Saxon, A. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-54856-4.00006-7
Fendrich, M., & Becker, J. (2020) · Journal of Social Service Research · doi:10.1080/01488376.2020.1755412
Outpatient opioid use disorder treatment for the ID physician
Muthulingam, D., Madden, L. M., & Altice, F. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-68328-9.00009-6
Meil, W. M., Farrell, W., & Satti, R. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98514
Kaffashian, M. R., Hadavi, M., Taghinezhad, F., Ahmadi, I., Ghorabi, S. T., Khalafzadeh, A., & Mozafari, A. (2022) · Journal of Advances in Medical and Biomedical Research · doi:10.30699/jambs.30.142.452
Nigatu, Y. T., Elton‐Marshall, T., & Hamilton, H. A. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2125268
The Critical Role of Pharmacists in Treating Older People in the Opioid Crisis
Watanabe, J. H. (2023) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2023.47
Mendoza, N. S., Cantelme, L., Ananian, C. D., Hernàndez, N., & Wohlert, B. (2023) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2023.2188722
Co-occurring Depressive and Substance Use Disorders
Bailey, S. W. (2023) · Springer Publishing Company eBooks · doi:10.1891/9780826158420.0009
Mendoza, N. S., Cantelme, L., Ananian, C. D., Hernàndez, N., & Wohlert, B. (2023) · Journal of Social Work Practice in the Addictions · doi:10.1080/1533256x.2023.2199103
Kleykamp, B. A., Clarke, S. B., & Acquavita, S. P. (2023) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197618431.013.11
Pater, J. A., Guha, S., Pfafman, R., Kerrigan, C., & Toscos, T. (2023) · Lecture notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering · doi:10.1007/978-3-031-34586-9_28
Lana-Lander, I., Muñoz-Galán, R., Vieira, J. A. P., Majó, X., Martínez-Carbonell, E., Muga, R., & Colom, J. (2023) · European Addiction Research · doi:10.1159/000528647
Association of substance use with outcomes in mildly ill COVID-19 outpatients
Pobee, R. A., Cable, T., Chan, D., Herrick, J. A., Durkalski‐Mauldin, V. L., Korley, F. K., Callaway, C. W., & Rios, M. D. (2023) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2023.09.017
Vallecillo, G., Perelló, R., Durán, X., Canosa, I., Roquer, A., Martinez, M. C., & Robles, M. J. (2024) · International Journal of Geriatrics and Gerontology · doi:10.29011/2577-0748.100079
González, E. M. Q., Gadea, M., & Espert, R. (2024) · Revista Española de Drogodependencias · doi:10.54108/10086
Lifestyle Medicine in Patient Care
Fagundes, C. P., Merlo, G., & Rippe, J. M. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640814.003.0015
Governance and Drug Prices: An Empirical Analysis within the European Monetary UnionPreprint
Vasileiou, E., & Chalkiadaki, A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5103251
Ali, F., Kaura, A., Russell, C., Bonn, M., Bruneau, J., Dasgupta, N., Imtiaz, S., Martel‐Laferrière, V., Rehm, J. T., Shahin, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26607484
Amundsen, E. J., Bretteville‐Jensen, A. L., & Rossow, I. M. (2022) · Figshare · doi:10.6084/m9.figshare.19624373
Sakakibara, K., Tobin, K. E., & Latkin, C. A. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2671343
Underdiagnosis of Disorders Due to Substance Use in an Academic Psychiatric Hospital
Eslami, M., Eyvaznejad, B., Rassa, S., Ansari, M., Gholami, J., Rahimi‐Movaghar, A., & Shadloo, B. (2026) · Substance Use & Misuse · doi:10.1080/10826084.2026.2704623
Bahí, A., & Dreyer, J. (2026) · Psychopharmacology · doi:10.1007/s00213-026-07167-9
Metadata
- Authors
- Bahorik, A. L., Satre, D. D., Kline-Simon, A. H., Weisner, C. M., & Campbell, C. I.
- Affiliations
- University of California, San Francisco (US)
- Corresponding author
- Bahorik, Amber L.
- Venue
- Journal of Addiction Medicine
- Published
- 2017-01
- Volume
- 11
- Issue
- 1
- Pages
- 3-9
- ISSN
- 1932-0620 (ISSN-L)
- 1935-3227
- PMC
- PMC5291754
- OpenAlex
- W2518262606
- Cited by
- 126
- References
- 33
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 14 · 2023: 22 · 2022: 25 · 2021: 21 · 2020: 20 · 2019: 8 · 2018: 4 · 2017: 5
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Addiction Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Drug Abuse (T32DA007250)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Keywords
- substance use disorders, alcoholism, cannabis use disorder, opioid use disorder, disease burden, comorbidities, Charlson Comorbidity Index, mortality risk, integrated care, privately insured patients
- MeSH terms
- Adult, California, Marijuana Abuse, Female, Humans, Male, Middle Aged, Mortality, Opioid-Related Disorders, Comorbidity, Delivery of Health Care, Integrated, Alcohol-Related Disorders, Electronic Health Records
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
